Designer antiandrogens join the race against drug resistance

eLife

Volumn 2013, Issue 2, 2013, Pages

  Josan, Jatinder S ^a   Katzenellenbogen, John A ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; ENZALUTAMIDE; FLUTAMIDE; MUTANT PROTEIN;

ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; COMPUTER SIMULATION; DRUG DESIGN; DRUG RECEPTOR BINDING; FLOW CYTOMETRY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MUTAGENESIS; NONHUMAN; POINT MUTATION; PROSTATE CANCER; MALE; MUTATION;

ANDROGEN ANTAGONISTS; DRUG DESIGN; HUMANS; MALE; MUTATION;

EID: 84879038388     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.00692     Document Type: Article

References (11)

1. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, et al. 2013. Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife 2:e00499. doi: 10.7554/eLife.00499.
2. Efstathiou E, Titus M, Tsavachidou D, Wen S, Hoang A, Ashe R, et al. 2012. Modulation of intracrine androgen signaling in bone metastatic castrate resistant prostate cancer (bmCRPC) by MDV3100. Cancer Res 72:2696. doi: 10.1158/1538-7445.AM2012-2696.
3. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, et al. 2003. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63:149-53.
4. Knudsen KE, Scher HI. 2009. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 15:4792-8. doi: 10.1158/1078-0432.CCR-08-2660.
5. Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, Nowakowska K, et al. 2012. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for Increasing abiraterone exposure or combining with MDV3100. Cancer Res 72:2176-82. doi: 10.1158/0008-5472.CAN-11-3980.
6. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. 2012. Increased survival with enzalutamide in prostate cancer after chemotherapy. New Engl J Med 367:1187-97. doi: 10.1056/NEJMoa1207506.
7. Shiau AK, Barstad D, Radek JT, Meyers MJ, Nettles KW, Katzenellenbogen BS, et al. 2002. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nature Struct Biol 9:359-64. doi: 10.1038/nsb787.
8. Taplin M-E, Balk SP. 2004. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91:483-90. doi: 10.1002/jcb.10653.
9. Taplin M-E, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, et al. 2003. Androgen receptor mutations in androgen-independent prostate cancer: cancer and leukemia group B study 9663. J Clin Oncol 21:2673-8. doi: 10.1200/JCO.2003.11.102.
10. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, et al. 1990. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173:534-40. doi: 10.1016/S0006-291X(05)80067-1.
11. Zheng Y, Zhu M, Srinivasan S, Nwachukwu JC, Cavett V, Min J, et al. 2012. Development of selective estrogen receptor modulator (SERM)-like activity through an indirect mechanism of estrogen receptor antagonism: defining the binding mode of 7-oxabicyclo[2.2.1]hept-5-ene scaffold core ligands. ChemMedChem 7:1094-100. doi: 10.1002/cmdc.201200048.